Phosphodiesterase 4D polymorphisms associate with the short-term outcome in ischemic stroke

Yan-li Song1,2,3,4,5,*, Chun-juan Wang1,2,3,4,*, Yi-ting Wu5, Jie Lin5, Peng-lian Wang1,2,3,4, Wan-liang Du1,2,3,4, Li Liu1,2,3,4, Jin-xi Lin1,2,3,4, Yi-long Wang1,2,3,4, Yong-jun Wang1,2,3,4 & Gai-fen Liu1,2,3,4

It has been demonstrated that phosphodiesterase 4D (PDE4D) genetic polymorphism is associated with ischemic stroke. However, the association between PDE4D gene and prognosis after ischemic stroke remains unknown. We consecutively enrolled ischemic stroke patients admitted to Beijing Tiantan Hospital from October 2009 to December 2013. Clinical, laboratory and imaging data upon admission were collected. All patients were followed up 3 months after stroke onset. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to assess the associations of genetic polymorphisms with 3-month outcome after ischemic stroke and different subtypes, under various genetic models. A total of 1447 patients were enrolled, and 3-month follow-up data were obtained from 1388 (95.92%). Multivariate regression analysis showed that SNP87 of PDE4D gene was associated with increased risk of unfavorable outcome after total ischemic stroke (OR = 1.47, 95%CI 1.12–1.93), as well as stroke due to large-artery atherosclerosis (OR = 1.49, 95%CI 1.04–2.11) and small-artery occlusion (OR = 1.76, 95%CI 1.05–2.96) under a recessive model. No association between SNP83 genotype and poor outcome was found. Overall, this study demonstrated that the TT genotype of SNP87 in PDE4D was associated with increased risk of poor outcome after total ischemic stroke, large-artery atherosclerosis and small-artery occlusion, in a Chinese population.

Stroke is the second most common cause of death worldwide and the first leading cause of mortality in China, with an annual mortality of approximately 1.6 million1–3. It has different subtypes, and ischemic stroke (IS) accounts for about 85%4. Traditional risk factors for ischemic stroke such as hypertension, dyslipidemia, diabetes mellitus, and smoking are well-established, but not fully known5,6. Various epidemiological studies from twins, case-control and cohort studies of familial aggregation suggest that genetic predisposition may contribute to IS, and it is more of a clinical syndrome rather than a disease due to numerous clinical, genetic, and lifestyle risk factors7,8.

One widely studied candidate gene is phosphodiesterase 4D (PDE4D), which was identified via genome-wide association studies (GWAS). PDE4D is located on chromosome 5q12 that spans a 1.6-Mb region and contains 24 exons, 8 splice variants and hundreds of gene variants. It belongs to a superfamily of phosphodiesterases (PDE4 family), and encodes cyclic adenosine monophosphate (cAMP) -specific 3',5'-cyclic phosphodiesterase 4D, which plays an important role in the degradation of cAMP9. The proliferation and migration of vascular smooth muscle cells and macrophages is responsible for atherosclerosis, and cAMP is involved in this process10. In 2003, Gretarsdottir et al. first identified the association of SNP83 in the PDE4D gene with carotid stroke in an Icelandic population11. Since then, many studies have found such association in various populations12. Woo et al. found that PDE4D was associated with ischemic stroke and, in particular, with cardio-embolic stroke among whites and blacks13. Milton et al. conducted a cohort study in Australia, and also detected a positive association of PDE4D...
and cardio-embolic stroke\(^4\). No association was found between \(PDE4D\) and ischemic stroke in German and Chinese populations\(^15,16\). These inconsistent results may be due to different allele frequencies across study populations, particularly in different ethnicities and geographical groups. In addition, several meta-analyses suggested that \(PDE4D\) was related to ischemic stroke, especially in Asian and Chinese populations\(^17–19\).

A few studies explored the association of genetic polymorphism and outcome after ischemic stroke\(^20–23\). However, to our knowledge, there are still no studies reporting the association of \(PDE4D\) genetics with prognosis.

Ischemic stroke has been classified into different subtypes due to different pathogenesis\(^24\). Therefore, in this study we aimed to investigate the association of \(PDE4D\) genetics with 3-month outcome after ischemic stroke, and its different subtypes classified by the Trial of Org10172 in Acute Stroke Treatment (TOAST) classification in a Chinese population.

**Results**

**Clinical characteristics.** A total of 1447 ischemic stroke patients were enrolled in the study, and 59 patients (4.08%) without 3-month data were excluded. The mean age of the included patients was (60.04 ± 3.01) years, and the male patients accounted for 75.1%. The baseline characteristics of patients are presented in Table 1.

Compared with patients presenting a favorable outcome, patients with unfavorable outcome were older (62.25 ± 2.26 vs. 55.98 ± 3.39 years, \(P < 0.001\)), with a significantly higher proportion of women (27.3% vs. 20.6%, \(P < 0.05\)), less history of hyperlipidemia (14.3% vs. 19.4%, \(P < 0.05\)), more history of ischemic stroke (27.3% vs. 18.6%, \(P < 0.001\)), and higher NIHSS on admission (6 (2–10) vs. 3 (1–5), \(P < 0.001\)). Differences in other demographics and medical history were not significant between the two groups. According to TOAST classification, the proportion of large-artery atherosclerosis was higher in the unfavorable outcome group (63.5% vs. 54.9%, \(P < 0.05\)).

**Distributions of SNP83 and SNP87 genotypes.** Distributions of the SNP83 and SNP87 genotypes are shown in Table 2. Genotype distributions of SNP87 (rs918592) and SNP83 (rs966221) both followed the

| Variables                        | Total   | Outcome                      |
|----------------------------------|---------|------------------------------|
|                                 |         | Unfavorable (mRS < 2) | Favorable (mRS ≥ 2) |
| N                                | 1388 (100.0) | 490 (35.3) | 898 (64.7) |
| Age (mean ± SD)                  | 60.04 ± 3.01 | 55.98 ± 3.39 | 62.25 ± 2.26 |
| Gender [n(%)]                    |         |                             |
| Male                             | 1042 (75.1) | 389 (79.4) | 653 (72.7) |
| Female                           | 346 (24.9) | 101 (20.6) | 245 (27.3) |
| Ethnic [n(%)]                    |         |                             |
| Han                              | 1356 (97.7) | 479 (97.8) | 877 (97.7) |
| Other                            | 32 (2.3) | 11 (2.2) | 21 (2.3) |
| Education [n(%)]                 |         |                             |
| Primary school or lower          | 805 (58.0) | 258 (52.7) | 547 (60.9) |
| Senior school or higher          | 583 (42.0) | 232 (47.3) | 351 (39.1) |
| History [n(%)]                   |         |                             |
| Smoking                          | 821 (60.5) | 306 (63.4) | 515 (58.9) |
| Drinking                         | 315 (25.3) | 120 (26.4) | 195 (24.6) |
| Hypertension                     | 853 (61.5) | 287 (58.6) | 566 (63.0) |
| Diabetes                         | 400 (28.8) | 130 (26.5) | 270 (30.1) |
| Hyperlipidemia                   | 223 (16.1) | 95 (19.4) | 128 (14.3) |
| Coronary heart disease           | 142 (10.2) | 46 (9.4) | 96 (10.7) |
| Atrial fibrillation              | 52 (3.7) | 12 (2.4) | 40 (4.5) |
| Ischemic stroke                  | 336 (24.2) | 91 (18.6) | 245 (27.3) |
| Cerebral hemorrhage              | 32 (2.3) | 12 (2.4) | 20 (2.2) |
| NIHSS on admission               | 4 (2–8) | 3 (1–5) | 6 (2–10) |

Table 1. Baseline characteristics according to the subgroup outcomes. Note: Continuous and categorical variables were tested by Student’s t-test and \(\chi^2\) analysis, respectively. NIHSS: National Institutes of Health Stroke Scale.
Hardy-Weinberg equilibrium \( (\chi^2 = 0.304, P_{\text{HWE}} = 0.582; \chi^2 = 0.656, P_{\text{HWE}} = 0.418, \text{respectively}) \). The minor allele frequencies (MAF) of rs918592 and rs966221 were 0.472 and 0.215, respectively.

**Associations of SNP83 and SNP87 with 3-month outcome after ischemic stroke and different subtypes.** Univariate logistic regression analysis showed significant association between SNP87 genotype and unfavorable outcome after ischemic stroke under the additive model (TT vs. CT vs. CC) \( (\text{OR} 1.19, 95\% \text{CI} 1.01–1.39) \) and recessive model (TT vs. CT + CC) \( (\text{OR} 1.47, 95\% \text{CI} 1.14–1.89) \). After adjustment for age, gender and NIHSS on admission, multivariate logistic regression analysis revealed that the association remained significant under the additive \( (\text{OR} 1.19, 95\% \text{CI} 1.01–1.40) \) and recessive \( (\text{OR} 1.47, 95\% \text{CI} 1.12–1.93) \) models (Table 3).

However, no association was found between the SNP83 genotype and unfavorable outcome after ischemic stroke.

In subgroup analysis based on the TOAST classification, we found significant association between SNP83 genotype and unfavorable outcome after stroke due to large-artery atherosclerosis \( (\text{OR} 1.49, 95\% \text{CI} 1.04–2.11) \) and small-artery occlusion \( (\text{OR} 1.76, 95\% \text{CI} 1.05–2.96) \) under a recessive model (Table 4) after adjustment for age, gender and NIHSS on admission. However, no association was found between the SNP83 genotype and unfavorable outcome in any stroke subtype.

| Genotype Total[n(%)] | Outcome[n(%)] | MAF | \( P_{\text{HWE}} \) |
|----------------------|---------------|-----|---------------------|
| SNP87(rs918592)      |               |     |                     |
| CC 302 (21.9)        | 110 (22.5)    | 192 (21.5) | 0.472               |
| CT 698 (50.6)        | 267 (54.7)    | 431 (48.3) | 0.582               |
| TT 380 (27.5)        | 111 (22.8)    | 269 (30.2) |                     |
| SNP83(rs966221)      |               |     |                     |
| AA 845 (61.2)        | 300 (61.6)    | 545 (61.0) | 0.215               |
| AG 477 (34.5)        | 165 (33.9)    | 312 (34.9) | 0.418               |
| GG 59 (4.3)          | 22 (4.5)      | 37 (4.1)    |                     |

**Table 2. Genotype of SNP 83 and SNP87 in PDE4D gene between different groups.** Note: SNP, single nucleotide polymorphism; MAF, minor allell frequency; HWE, Hardy-Weinberg equilibrium.

| Genetic model | OR  | 95%CI | Adjusted OR \(^\dagger\) | 95%CI | Adjusted OR \(^\ddagger\) | 95%CI |
|---------------|-----|-------|------------------------|------|------------------------|------|
| SNP87         |     |       |                        |      |                        |      |
| Additive model| 1.19| 1.01–1.39 | 1.19                   | 1.01–1.40 | 1.18                   | 1.00–1.39 |
| Recessive model| 1.47| 1.14–1.89 | 1.47                   | 1.12–1.93 | 1.47                   | 1.12–1.93 |
| Dominant model| 1.06| 0.81–1.38 | 1.06                   | 0.80–1.40 | 1.03                   | 0.78–1.37 |
| SNP83         |     |       |                        |      |                        |      |
| Additive model| 1.01| 0.83–1.22 | 1.01                   | 0.83–1.24 | 1.02                   | 0.84–1.26 |
| Recessive model| 0.93| 0.54–1.59 | 0.92                   | 0.52–1.63 | 0.91                   | 0.51–1.61 |
| Dominant model| 1.02| 0.81–1.28 | 1.03                   | 0.81–1.31 | 1.05                   | 0.83–1.34 |

**Table 3. Association between PDE4D genotype and outcome after ischemic stroke.** Note: \(^\dagger\) adjustment for age, gender and NIHSS on admission; \(^\ddagger\) adjustment for age, gender, education, history of hypertension, diabetes, hyperlipidemia, atrial fibrillation, ischemic stroke, NIHSS on admission.

| Stroke subtype | Additive model | Recessive model | Dominant model |
|----------------|---------------|----------------|---------------|
| SNP87          | OR  | 95%CI  | OR  | 95%CI  | OR  | 95%CI  |
| Large-artery atherosclerosis | 1.20 | 0.97–1.49 | 1.49 | 1.04–2.11 | 1.08 | 0.75–1.56 |
| Cardio-embolism  | 0.86 | 0.58–1.35 | 1.26 | 0.34–4.66 | 0.49 | 0.12–2.07 |
| Small-artery occlusion | 1.37 | 0.99–1.89 | 1.76 | 1.05–2.96 | 1.30 | 0.75–2.25 |
| SNP83          | OR  | 95%CI  | OR  | 95%CI  | OR  | 95%CI  |
| Large-artery atherosclerosis | 0.90 | 0.69–1.16 | 0.68 | 0.34–1.34 | 0.92 | 0.68–1.26 |
| Cardio-embolism  | 1.17 | 0.48–2.82 | 1.00 | 0.13–7.89 | 1.30 | 0.41–4.06 |
| Small-artery occlusion | 1.20 | 0.79–1.82 | 2.15 | 0.52–8.85 | 1.15 | 0.71–1.85 |

**Table 4. Association between PDE4D genotype and outcome after ischemic stroke subtypes.** Note: adjustment for age, gender and NIHSS on admission.
Discussion
In this study, we found that the TT genotype of SNP87 in PDE4D was associated with an increased risk for 3-month unfavorable outcome after total ischemic stroke, as well as stroke due to large-artery atherosclerosis and small-artery occlusion, in a Chinese population. However, no association was found between the SNP83 genotype and unfavorable outcome after ischemic stroke or any subtype.

After Gretarsdottir et al. identified PDE4D as a susceptible gene for ischemic stroke11, a large number of studies explored the association of single nucleotide polymorphisms across this gene with the disease. PDE4D is located in chromosome 5q12, and encodes cyclic adenosine monophosphate (cAMP) -specific 3′,5′-cyclic phosphodiesterase 4D. PDE4D selectively degrades the second messenger cAMP in vascular smooth muscle cells and activates macrophages, which is a key signaling molecule mediating proliferation, migration and secretion of cells related to atherosclerosis and plaque stability. Thus, PDE4D has been shown to contribute to ischemic stroke via the atherosclerotic pathway10,25-27.

Due to varying allele frequencies among different populations, ethnicities and geographies, several studies focused on the association of PDE4D with ischemic stroke, obtaining conflicting results, even in Chinese populations13–16,28–32. He et al. demonstrated a strong association of rs918592 in the PDE4D gene with ischemic stroke in the Henan Han population, and also suggested that rs918592 and rs2910829 polymorphisms were associated with ischemic stroke in young Chinese individuals31–32. Shao et al. found no association of PDE4D polymorphisms with ischemic stroke in a southeastern Chinese population32. Liu et al. conducted a meta-analysis of Chinese population studies, and showed a positive correlation between rs2910829 and ischemic stroke33. In the present study, we evaluated the association of PDE4D with 3-month outcome after ischemic stroke in a Chinese population. In this cohort, the patients were relatively young with a mean age of about 60 years, which was slightly younger compared with the patients in the China National Stroke Registry (mean age of about 63.8 years)33. We found that the SNP87 genotype in PDE4D was associated with an increased risk of 3-month unfavorable outcome after ischemic stroke under the additive and recessive models. Further, multivariate analysis showed that this association was still significant under the additive and recessive models after adjustment for age, gender, NIHSS on admission and even other clinical characteristics. The results were consistent with the findings from previous studies on PDE4D genetics with the incidence of ischemic stroke among Chinese populations34,31,32. However, no association was found between SNP83 genotype in PDE4D and unfavorable outcome after ischemic stroke, which may be explained by the relatively small sample size.

Ischemic stroke is a complicated disease and is divided into five subtypes according to TOAST classification including large-artery atherosclerosis, cardio-embolism, small-artery occlusion, stroke of other determined etiology and stroke of undetermined etiology34. As the subtypes have different pathogenesis, genetic polymorphisms may be susceptible to specific subtype. In this study, we performed a subgroup analysis by stroke subtype, and found that SNP87 was associated with an increased risk of unfavorable outcome after stroke due to large-artery atherosclerosis and small-artery occlusion, under a recessive model. This result can be explained by the role of PDE4D in atherosclerosis, as mentioned above. Usually, cardio-embolism is associated with particularly poor outcome35. However, we did not find such association in the current study. This may be due to the relatively small sample size of the subtype caused by cardio-embolism. Therefore, additional studies with larger sample are needed to demonstrate this association.

Our study has a few advantages. First, ischemic stroke manifests different pathogenesis, and the PDE4D gene may be associated with a specific subtype. Therefore, we conducted subgroup analysis according to the TOAST classification. Further, IS subtype was classified by two experienced neurologists, which improved the accuracy of IS subtype classification. Finally, with more comprehensive etiological investigations (e.g. most patients performed imaging examination), IS subtype classification was more precise, and more patients were classified into other subtypes, thus leading to a lower proportion of undetermined etiology.

However, several potential limitations exist in the present study. First, we only selected patients from Beijing Tiantan Hospital, which may not be representative of all patients in China, and might lead to a bias. Therefore, the percentage of GG genotype of SNP83 was only 4.3%, which may be underpowered to detect the effect. Second, we only focused on SNP87 and SNP83 genetic polymorphisms in PDE4D, not assessing other genes or environmental factors. The potential role of PDE4D genetic polymorphisms may be reduced or absent in other gene-gene or gene-environment interactions. In addition, sample size was relatively small. Therefore, additional studies in other populations, with larger sample size, are needed to demonstrate the association of genetic polymorphisms with IS susceptibility.

Methods
Study population. Ischemic stroke patients were consecutively enrolled at the Beijing Tiantan Hospital from October 2009 to December 2013. IS was defined as a loss of global or focal cerebral function persisting for >24 hours, with corresponding infarction on brain imaging and a probable vascular cause excluding non-vascular causes (such as primary and metastatic neoplasms, post-seizure paralysis, or head trauma), and intracerebral hemorrhage on computed tomography (CT) or magnetic resonance imaging (MRI)36. Inclusion criteria were: (1) >18 years old; (2) acute ischemic stroke within 14 days; (3) patients undergoing diffusion weighted imaging (DWI) of the brain; blood samples drawn within 48 hours for DNA extraction. Patients diagnosed with silent cerebral infarction, transient ischemic attack (TIA), intracerebral hemorrhage (ICH) or subarachnoid hemorrhage (SAH) were excluded.

This study was approved by the Ethics Committee of Beijing Tiantan Hospital, Capital Medical University (Approval No. 2009-005). All experiments were conducted in compliance with national guidelines, following the Ethics and methods for biological rhythm research on animals and humans37. Written informed consent was obtained from each patient or legal proxy.
Baseline data collection and follow-up. Clinical data were collected, including demographics, medical history, family history, pre-stroke modified Rankin Scale (mRS), National Institutes of Health Stroke Scale (NIHSS) on admission, physical and neurological examinations, laboratory data, electrocardiogram (ECG), ultrasonic cardiogram (UCG), carotid artery ultrasound findings, transcranial Doppler, brain CT and/or MRI examinations, and high-resolution MRI or transesophageal echocardiography (TEE) if available. The stroke subtype of each patient according to the TOAST classification was identified independently by two experienced neurologists (Y.L.S. and C.J.W.) in Beijing Tiantan Hospital before patient discharge from the hospital. Patients with large-artery atherosclerosis should have clinical and brain imaging findings of either significant (>50%) stenosis or occlusion of intra-/extracranial arterial artery, presumably due to atherosclerosis. The stenosis evaluation of intracranial supplying arteries were assessed by computed tomography angiography (CTA) or magnetic resonance angiography (MRA) or digital subtraction angiography (DSA) and that of extracranial supplying arteries were assessed by carotid ultrasonography, carotid CTA, contrast-enhanced MR angiography (CEMRA) or DSA. Both neurologists were blinded to the follow-up data and genotype information. All patients were followed up by telephone at 3 months after IS onset by trained interviewers. The interviewers were blinded to patient’s clinical symptoms and genotypes. Unfavorable outcome was defined as modified Rankin Scale (mRS) ≥ 2.8

PDE4D genotypin. DNA was extracted from peripheral white blood cells by the phenol–chloroform method9. The SNP83 (rs966221) and SNP87 (rs918592) genotypes in PDE4D were determined by polymerase chain reaction (PCR). PDE4D genotyping of the included population was performed by time-of-flight mass spectrometry on a MassARRAY platform equipped with the iPLEX genotyping technology.

Statistical analysis. Patient characteristics were presented as mean ± standard deviation (SD) for continuous variables, or absolute count and percentage for categorical ones. The χ²-test and Student’s t-test were used to assess categorical and continuous variables, respectively. The χ²-test was also used to assess the Hardy-Weinberg equilibrium (HWE). Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to assess the associations of PDE4D genetic polymorphisms with outcome after ischemic stroke and its different subtypes under additive, dominant and recessive genetic models. Unfavorable outcome was defined as modified Rankin Scale (mRS) ≥ 2.8. For SNP87, the additive model was TT vs. CC; dominant and recessive models were TT + CT vs. CC and TT vs. CT + CC, respectively. For SNP 83, additive, dominant, and recessive models were GG vs. AA, GG + AG vs. AA, and GG vs. AG + AA, respectively. Sample size was calculated with PASS software version 11.0, and the sample size required was 1277 with the assumption that the minor allele frequency was 20%, Odds Ratio was 1.5, power was 0.8, and alpha was 0.05. 20% Odds Ratio was 1.5, power was 0.8, and alpha was 0.05 was considered statistically significant. Statistical analyses were performed with the SAS software version 9.4 (SAS Institute Inc., Cary, NC).

References
1. Yang, G. et al. Rapid health transition in China, 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet 381, 1987–2015 (2013).
2. Murray, C. J. & Lopez, A. D. Measuring the global burden of disease. The New England journal of medicine 369, 448–457 (2013).
3. Liu, L., Wang, D., Wong, K. S. & Wang, Y. Stroke and stroke care in China: huge burden, significant workload, and a national priority. Stroke; a journal of cerebral circulation 42, 3651–3654 (2011).
4. Rosand, J., Bayley, N., Rost, N. & de Bakker, P. I. Many hypotheses but no replication for the association between PDE4D and stroke. Nat Genet 38, 1091–1092 (2006).
5. Meschia, J. F., Worrall, B. B. & Rich, S. S. Genetic susceptibility to ischemic stroke. Nature reviews. Neurology 7, 369–378 (2011).
6. Dichgans, M. Genetics of ischaemic stroke. The Lancet. Neurology 6, 149–161 (2007).
7. Dichgans, M. & Markus, H. S. Genetic association studies in stroke: methodological issues and proposed standard criteria. Stroke; a journal of cerebral circulation 36, 2027–2031 (2005).
8. Flossmann, E., Schulz, U. G. & Rothwell, P. M. Systematic review of methods and results of studies of the genetic epidemiology of ischemic stroke. Stroke; a journal of cerebral circulation 35, 212–227 (2004).
9. Munshi, A. & Kaul, S. Stroke genomics—focus on PDE4D gene. International journal of stroke: official journal of the International Stroke Society 3, 188–192 (2008).
10. Houslay, M. D. & Adams, D. R. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 370, 1–18 (2003).
11. Greitardsdottir, S. et al. The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. Nature genetics 35, 131–138 (2003).
12. Das, S., Roy, S. & Munshi, A. Association between PDE4D gene and ischemic stroke: recent advancements. The International journal of neuroscience 126, 577–583 (2016).
13. Woo, D. et al. Association of phosphodiesterase 4D with ischemic stroke - A population-based case-control study. Stroke; a journal of cerebral circulation 37, 371–376 (2006).
14. Milton, A. G. et al. Association of the phosphodiesterase 4D (PDE4D) gene and cardioembolic stroke in an Australian cohort. International journal of Stroke 6, 480–486 (2011).
15. Kuhlenbaumer, G. et al. Evaluation of single nucleotide polymorphisms in the phosphodiesterase 4D gene (PDE4D) and their association with ischemic stroke in a large German cohort. Journal of neurology, neurosurgery, and psychiatry 77, 521–524 (2006).
16. Shao, M. et al. Ischemic stroke risk in a southeastern Chinese population: Insights from 5-lipoxygenase activating protein and phosphodiesterase 4D single-nucleotide polymorphisms. Journal of the Formosan Medical Association = Taiwan yi zhi 114, 422–429 (2014).
17. Yoon, D., Park, S. K., Kang, D., Park, T. & Park, J. W. Meta-Analysis of Homogeneous Subgroups Reveals Association between PDE4D Gene Variants and Ischemic Stroke. Neuroepidemiology 36, 213–222 (2011).
18. Liu, X. et al. Genetic polymorphism in PDE4D gene and risk of ischemic stroke in Chinese population: a meta-analysis. Plos one 8, e66374 (2013).
19. Yan, Y. et al. Association between phosphodiesterase 4D polymorphism SNP83 and ischemic stroke. Journal of the neurological sciences 338, 3–11 (2014).
20. Hsieh, Y. C. et al. Association between genetic variant on chromosome 12p13 and stroke survival and recurrence: a one year prospective study in Taiwan. Journal of biomedical science 19, 1 (2012).
21. Heuschmann, P. U. et al. Three-month stroke outcome: the European Registers of Stroke (EROS) investigators. Neurology 76, 159–165 (2011).
Phosphodiesterase 4D polymorphisms associate with the short-term outcome in ischemic stroke.

How to cite this article: Song, Y.- et al. Phosphodiesterase 4D polymorphisms associate with the short-term outcome in ischemic stroke. Sci. Rep. 7, 42914; doi: 10.1038/srep42914 (2017).

Acknowledgements
This research was supported by a grant from the National Natural Science Foundation of China (Grant No. 81200914), by a grant from the Ministry of Science and Technology and the Ministry of Health of the People’s Republic of China (Grant No. 2011BAI08B01, 2013BAI09B03, 2015BAI12B02, 2015BAI12B04), Beijing Biobank of Cerebral Vascular Disease (D131100005313003), Program of Talents by Beijing Municipal (2010D003034000012), Beijing Municipal Science & Technology Commission (D131100002313002), The Capital Health Research and Development of Special(2016-1-2041) and the Talents Project of Beijing (2014000021469G225). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author Contributions
Y.L.S. and C.J.W. identified the TOAST classification, analyzed the data and wrote the manuscript. Y.P.W., J.L., P.L.W., W.L.D., L.L. and J.X.L. performed and supervised the research. Y.L.W., Y.J.W. and G.F.L. designed the study.

Additional Information
Competing financial interests: The authors declare no competing financial interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2017